Waning of Antibody Response Among Vaccinees who Received Two Doses of Covishield Vaccine.
J Glob Infect Dis
; 15(1): 19-22, 2023.
Article
in English
| MEDLINE | ID: covidwho-2262247
ABSTRACT
Introduction:
There are limited data available on the long-term presence of SARS-CoV-2-specific binding antibodies and neutralizing antibodies in circulation among the elderly population. This study aims to examine levels of anti-SARS-CoV-2 antibodies in vaccines who have completed at least 6 months since the second vaccine dose. A cross-sectional study was conducted from November 2021 to January 2022 among 199 vaccines aged 60 years and above residing in Belagavi city, who received two doses of the Covishield vaccine.Methods:
Antibody response to SARS-COV-2 virus whole cell antigen was measured by a kit COVID KAWACH IgG Micro LISA (J Mitra and Company, India) in 199 participants who had completed at least 6 months after receiving the second dose of Covishield vaccine. The antibody response was measured as a ratio of optical density (OD) in the participant's sample to the mean OD in negative control test by normal (T/N). Independent Kruskal-Wallis test was applied to test the difference between the T/N ratio by months of vaccination since the second dose and by the age group strata.Results:
The median T/N values among participants who completed 6, 7, 8, and 9 months since the second vaccine dose were 14.17, 10.46, 7.93, and 5.11, respectively, and this decline in T/N values was statistically significant. Antibody response values showed a decline with increasing age for participants in the age strata 60-69, 70-79, and 80 and above, respectively.Conclusions:
A significant decline was observed in antibody response over 9 months supporting the administration of booster dose of vaccine.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
/
Randomized controlled trials
Topics:
Vaccines
Language:
English
Journal:
J Glob Infect Dis
Year:
2023
Document Type:
Article
Affiliation country:
Jgid.jgid_128_22
Similar
MEDLINE
...
LILACS
LIS